YTHDF1 exhibited carcinogenic effects in colorectal cancer (Chen et al., 2024[16]), esophageal cancer (Zhang et al., 2024[342]), breast cancer (Wang et al., 2024[267]), gastric cancer (Song et al., 2024[215]), gallbladder cancer (Chen et al., 2024[18]), non-small cell lung cancer (Sun et al., 2024[225]), hepatocellular carcinoma (Zhang et al., 2024[349]), and bladder cancer (Zhu et al., 2023[373]). Here, YTHDF1 is linked to esophageal cancer.